That would be true of ordinary antibiotics. But Brilicidin's unique MOA makes resistance MUCH less likely to occur. The proof of this assertion is that B is a Defensin Mimetic. That means Brilicidin has the same MOA that the human body's own defensins have had for many thousands of years. If bacteria was going to develop resistance to being punctured by defensins, it would probably have happened by now.
Quote:
Echo; my understanding is that in order to prevent bacteria from developing resistance to B, the medical establishment will have to carefully control its use. If B is added to consumer products, its useful life may be shortened drastically. IMO.
- windansea